Research record: Immunohistochemistry-quantified EGFR mutant protein expression percentage outperforms next-generation sequencing-derived mutational abundance for predicting tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
Published in Oncol Lett; first publication date 2026-11-10. PMID 43054699.
This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.
